| Literature DB >> 28525717 |
Alessia Chelini1, Simone Brogi1, Marco Paolino1, Angela Di Capua1,2, Andrea Cappelli1, Gianluca Giorgi1, Mersedeh Farzad3, Lorenzo Di Cesare Mannelli4, Laura Micheli4, Carla Ghelardini4, Maurizio Anzini1.
Abstract
LDN-212320 (3) was found to be a potent EAAT2 activator at a translational level, restoring the normal clearance of glutamate and providing neuronal protection. Since the pharmacologic activation of EAAT2 represents a valuable strategy to relieve neuropathic pain, we synthesized novel activators (4a-f) of EAAT2. Among them 4f, analyzed in comparison with 3 by different paradigms in a rat model of oxaliplatin-induced neuropathic pain, showed the better antihypersensitive profile being able to fully counteract the oxaliplatin-induced neuropathy.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28525717 DOI: 10.1021/acs.jmedchem.7b00383
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446